JP2021534160A - 疾患処置のためのリルゾール口腔内崩壊錠の使用 - Google Patents
疾患処置のためのリルゾール口腔内崩壊錠の使用 Download PDFInfo
- Publication number
- JP2021534160A JP2021534160A JP2021507740A JP2021507740A JP2021534160A JP 2021534160 A JP2021534160 A JP 2021534160A JP 2021507740 A JP2021507740 A JP 2021507740A JP 2021507740 A JP2021507740 A JP 2021507740A JP 2021534160 A JP2021534160 A JP 2021534160A
- Authority
- JP
- Japan
- Prior art keywords
- riluzole
- administration
- cancer
- disease
- vas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023179961A JP2024010017A (ja) | 2018-08-16 | 2023-10-19 | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862764864P | 2018-08-16 | 2018-08-16 | |
| US62/764,864 | 2018-08-16 | ||
| PCT/US2019/046709 WO2020037152A1 (en) | 2018-08-16 | 2019-08-15 | Use of riluzole oral disintigrating tablets for treating diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179961A Division JP2024010017A (ja) | 2018-08-16 | 2023-10-19 | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534160A true JP2021534160A (ja) | 2021-12-09 |
| JP2021534160A5 JP2021534160A5 (cg-RX-API-DMAC7.html) | 2022-03-02 |
Family
ID=69525906
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507740A Pending JP2021534160A (ja) | 2018-08-16 | 2019-08-15 | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
| JP2023179961A Pending JP2024010017A (ja) | 2018-08-16 | 2023-10-19 | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023179961A Pending JP2024010017A (ja) | 2018-08-16 | 2023-10-19 | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
Country Status (14)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023531919A (ja) * | 2020-06-24 | 2023-07-26 | バイオヘイブン・セラピューティクス・リミテッド | 強迫性障害を治療するための組成物及び方法 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| LT4243797T (lt) | 2020-11-16 | 2026-06-10 | Orcosa Inc. | Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN114177153B (zh) * | 2021-12-20 | 2023-04-07 | 平顶山市第二人民医院 | 一种利鲁唑口崩片及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003524622A (ja) * | 1999-04-08 | 2003-08-19 | アール.ピー. シェーラー コーポレイション | 魚類ゼラチン含有の急速分散型投与形態 |
| JP2017535613A (ja) * | 2014-11-21 | 2017-11-30 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドBiohaven Pharmaceutical Holding Company Ltd. | リルゾールの舌下製剤 |
| JP2018508525A (ja) * | 2015-03-03 | 2018-03-29 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドBiohaven Pharmaceutical Holding Company Ltd. | リルゾールプロドラッグおよびそれらの使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| WO2004047793A1 (en) * | 2002-11-26 | 2004-06-10 | Alk-Abelló A/S | Pharmaceutical allergen product |
| US9241902B2 (en) * | 2003-12-17 | 2016-01-26 | R.P. Scherer Technologies, Llc | Chewable soft capsules containing ungelatinized starch |
| ES2819303T3 (es) * | 2005-04-05 | 2021-04-15 | Univ Yale | Agentes moduladores del glutamato en el tratamiento de trastornos mentales |
| US20080260823A1 (en) * | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
| WO2011019375A1 (en) * | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| US9041556B2 (en) | 2011-10-20 | 2015-05-26 | Apple Inc. | Method for locating a vehicle |
| US9434704B2 (en) * | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| CA2967659A1 (en) * | 2014-11-21 | 2016-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual administration of riluzole |
| US10258611B2 (en) * | 2014-11-26 | 2019-04-16 | Medicinova, Inc. | Combination of ibudilast and riluzole and methods of using same |
| MX2019009038A (es) * | 2017-01-31 | 2019-12-09 | L Manfredi Paolo | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
-
2019
- 2019-08-15 CN CN201980054201.0A patent/CN112584831A/zh active Pending
- 2019-08-15 SG SG11202100880VA patent/SG11202100880VA/en unknown
- 2019-08-15 ES ES19849456T patent/ES2987802T3/es active Active
- 2019-08-15 JP JP2021507740A patent/JP2021534160A/ja active Pending
- 2019-08-15 AU AU2019322889A patent/AU2019322889A1/en not_active Abandoned
- 2019-08-15 KR KR1020217007246A patent/KR20210045423A/ko not_active Ceased
- 2019-08-15 BR BR112021002692-4A patent/BR112021002692A2/pt not_active Application Discontinuation
- 2019-08-15 US US17/268,072 patent/US20210315865A1/en active Pending
- 2019-08-15 WO PCT/US2019/046709 patent/WO2020037152A1/en not_active Ceased
- 2019-08-15 MX MX2021001563A patent/MX2021001563A/es unknown
- 2019-08-15 EP EP19849456.9A patent/EP3836922B1/en active Active
- 2019-08-15 EA EA202190544A patent/EA202190544A1/ru unknown
-
2021
- 2021-01-28 PH PH12021550218A patent/PH12021550218A1/en unknown
- 2021-02-04 IL IL280657A patent/IL280657A/en unknown
- 2021-02-08 MX MX2024007642A patent/MX2024007642A/es unknown
-
2023
- 2023-10-19 JP JP2023179961A patent/JP2024010017A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003524622A (ja) * | 1999-04-08 | 2003-08-19 | アール.ピー. シェーラー コーポレイション | 魚類ゼラチン含有の急速分散型投与形態 |
| JP2017535613A (ja) * | 2014-11-21 | 2017-11-30 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドBiohaven Pharmaceutical Holding Company Ltd. | リルゾールの舌下製剤 |
| JP2018508525A (ja) * | 2015-03-03 | 2018-03-29 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドBiohaven Pharmaceutical Holding Company Ltd. | リルゾールプロドラッグおよびそれらの使用 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023531919A (ja) * | 2020-06-24 | 2023-07-26 | バイオヘイブン・セラピューティクス・リミテッド | 強迫性障害を治療するための組成物及び方法 |
| JP7805969B2 (ja) | 2020-06-24 | 2026-01-26 | バイオヘイブン・セラピューティクス・リミテッド | 強迫性障害を治療するための組成物及び方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024007642A (es) | 2024-07-04 |
| EP3836922A4 (en) | 2022-05-04 |
| JP2024010017A (ja) | 2024-01-23 |
| SG11202100880VA (en) | 2021-02-25 |
| WO2020037152A1 (en) | 2020-02-20 |
| AU2019322889A1 (en) | 2021-03-04 |
| PH12021550218A1 (en) | 2021-12-06 |
| EP3836922B1 (en) | 2024-08-07 |
| IL280657A (en) | 2021-03-25 |
| US20210315865A1 (en) | 2021-10-14 |
| EP3836922A1 (en) | 2021-06-23 |
| MX2021001563A (es) | 2021-06-15 |
| EA202190544A1 (ru) | 2021-06-18 |
| EP3836922C0 (en) | 2024-08-07 |
| CA3109769A1 (en) | 2020-02-20 |
| ES2987802T3 (es) | 2024-11-18 |
| BR112021002692A2 (pt) | 2021-05-11 |
| CN112584831A (zh) | 2021-03-30 |
| KR20210045423A (ko) | 2021-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3836922B1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| JP6090836B2 (ja) | 化学療法剤の抗腫瘍活性増強剤 | |
| EP3220891B1 (en) | Sublingual formulation of riluzole | |
| US20260014123A1 (en) | Use of riluzole oral disintegrating tablets for treating diseases | |
| WO2023186827A1 (en) | 5-methoxy-n,n-dimethyltryptamine for the treatment of postpartum depression | |
| US20210290651A1 (en) | Methods of treating viral infections using inhibitors of nucleotide synthesis pathways | |
| JP2020513005A (ja) | Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物 | |
| AU2023428136A1 (en) | 5-meo-dmt for use in the treatment of postpartum depression | |
| Nehra et al. | Olutasidenib: A ray of hope in the treatment of acute myeloid leukaemia | |
| CA3109769C (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| EA046859B1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| Danyeli et al. | Ketamine in Psychiatric Disorders | |
| JP2025510915A (ja) | 産後うつ病の処置のための5-メトキシ-n,n-ジメチルトリプタミン | |
| HK1243318A1 (en) | Sublingual formulation of riluzole | |
| HK1243318B (en) | Sublingual formulation of riluzole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220221 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221220 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230510 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230620 |